114 related articles for article (PubMed ID: 27957707)
1. Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.
Pan Y; Hu C; Chen PH; Gu YH; Qiao QY; Pan LH; Zhou DC; Gu HF; Fu SK; Jin HM
Eur J Clin Pharmacol; 2017 Mar; 73(3):267-278. PubMed ID: 27957707
[TBL] [Abstract][Full Text] [Related]
2. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J
J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207
[TBL] [Abstract][Full Text] [Related]
3. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.
Ryerson CJ; Nayar S; Swiston JR; Sin DD
Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497
[TBL] [Abstract][Full Text] [Related]
5. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
[TBL] [Abstract][Full Text] [Related]
6. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
[TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
8. Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis.
Yuan W; Li Y; Wang J; Li J; Gou S; Fu P
Nephrology (Carlton); 2015 Jul; 20(7):459-66. PubMed ID: 25753148
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Hemodynamic Effects of Endothelin Receptor Antagonists in Patients With Heart Failure.
Xiong B; Nie D; Cao Y; Zou Y; Yao Y; Tan J; Qian J; Rong S; Wang C; Huang J
Int Heart J; 2017 May; 58(3):400-408. PubMed ID: 28539568
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
Zhou Y; Chi J; Huang Y; Dong B; Lv W; Wang YG
Diabet Med; 2021 Jan; 38(1):e14411. PubMed ID: 33000477
[TBL] [Abstract][Full Text] [Related]
11. Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials.
Deng H; Zhang BL; Tong JD; Yang XH; Jin HM
J Rheumatol; 2021 Jul; 48(7):1082-1089. PubMed ID: 32801136
[TBL] [Abstract][Full Text] [Related]
12. All-cause mortality and cardiovascular events with nicorandil in patients with IHD: systematic review and meta-analysis of the literature.
Luo B; Wu P; Bu T; Zeng Z; Lu D
Int J Cardiol; 2014 Oct; 176(3):661-9. PubMed ID: 25217220
[TBL] [Abstract][Full Text] [Related]
13. Clarithromycin use and the risk of mortality and cardiovascular events: A systematic review and meta-analysis.
You CH; Lin CK; Chen PH; Park S; Chen YY; Khan N; Papatheodorou SI; Chen ST
PLoS One; 2019; 14(12):e0226637. PubMed ID: 31881052
[TBL] [Abstract][Full Text] [Related]
14. A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension.
Zhang YJ; Wang N; Gu ZC; Wei AH; Cheng AN; Fang SS; Du HL; Wang LZ; Zhang GQ
Cardiovasc Diagn Ther; 2019 Jun; 9(3):239-249. PubMed ID: 31275814
[TBL] [Abstract][Full Text] [Related]
15. Endothelin receptor antagonism during preeclampsia: a matter of timing?
Hitzerd E; Neuman RI; Mirabito Colafella KM; Reiss IKM; van den Meiracker AH; Danser AHJ; Visser W; Versmissen J; Saleh L
Clin Sci (Lond); 2019 Jun; 133(12):1341-1352. PubMed ID: 31221823
[TBL] [Abstract][Full Text] [Related]
16. The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis.
Gu ZC; Zhang YJ; Pan MM; Zhang C; Liu XY; Wei AH; Su YJ
Medicine (Baltimore); 2018 Mar; 97(11):e0122. PubMed ID: 29538209
[TBL] [Abstract][Full Text] [Related]
17. Update on Endothelin Receptor Antagonists in Hypertension.
Burnier M
Curr Hypertens Rep; 2018 May; 20(6):51. PubMed ID: 29779164
[TBL] [Abstract][Full Text] [Related]
18. Association of sleep disorders, chronic pain, and fatigue with survival in patients with chronic kidney disease: a meta-analysis of clinical trials.
Yang XH; Zhang BL; Gu YH; Zhan XL; Guo LL; Jin HM
Sleep Med; 2018 Nov; 51():59-65. PubMed ID: 30099353
[TBL] [Abstract][Full Text] [Related]
19. Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.
Gueneau de Mussy P; Sidharta PN; Wuerzner G; Maillard MP; Guérard N; Iglarz M; Flamion B; Dingemanse J; Burnier M
Clin Pharmacol Ther; 2021 Mar; 109(3):746-753. PubMed ID: 32897570
[TBL] [Abstract][Full Text] [Related]
20. Endothelin antagonists in clinical trials: lessons learned.
Barton M; Kohan DE
Contrib Nephrol; 2011; 172():255-260. PubMed ID: 21894005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
